The protein expression systems market is projected to reach USD 2,850.5 million by 2022 from an estimated USD 1,654.0 million in 2017, at a CAGR of 11.5%. The growth of this market is attributed to rising prevalence of chronic disorders, availability of funding for protein-based research activities and growth in life sciences and biopharmaceutical industries.
Download PDF Brochure Here :http://www.marketsandmarkets.com/pdfdownload.asp?id=180323924
Product launches, acquisitions, and partnerships are the main strategies followed by key players in the protein expression market. Some of the leading players that adopted these strategies include Thermo Fisher Scientific Inc. (U.S.), Merck KGaA (Germany), GenScript Biotech Corporation (China), and Agilent Technologies Inc. (U.S.).
Thermo Fisher Scientific Inc. (U.S.) is a key player in the protein expression market. The company adopted product launches and acquisitions as its key strategies in order to enhance its product portfolio. For instance, in June 2016, the company launched the Nano LC System and Columns which is used in protein purification and protein expression process. In February 2014, Thermo Fisher Scientific Inc. acquired Life Technologies Inc. (U.S.). After this acquisition, Thermo Fisher created a new business segment—Life Sciences Solutions, which includes a broad range of protein expression systems and their related products.
Merck KGaA (Germany) accounted for the second largest market share of the protein expression market in 2016. The company focuses on acquisitions and partnerships to maintain its leading position in the protein expression market. For instance, in November 2015, Merck KGaA acquired Sigma-Aldrich Co. LLC. (U.S.), another established player in the life science industry. Sigma-Aldrich offers a broad range of protein expression products. This acquisition will increase the dominance of Merck KGaA in the protein expression market. In 2017, Merck KGaA and SystImmune Inc. (U.S.) made a strategic partnership to expand its protein expression portfolio.
GenScript Biotech Corporation (China) also accounts for the significant market share of the protein expression market. It concentrates on product launches as a key strategy to enhance its protein expression product offering. For example, in October 2016, the company launched the CHO-based glutamine synthetase bioproduction cell line service. This service was aimed to reduce the manufacturing cost of biologics.